Startseite Risk factors affecting the development of nephrocalcinosis, the most common complication of hypophosphatemic rickets
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Risk factors affecting the development of nephrocalcinosis, the most common complication of hypophosphatemic rickets

  • Melikşah Keskin EMAIL logo , Şenay Savaş-Erdeve , Elif Sağsak , Semra Çetinkaya und Zehra Aycan
Veröffentlicht/Copyright: 23. Juli 2015

Abstract

The aim of the present study was to analyse the effects of combined treatment with calcitriol and phosphate, to find out the incidence of the nephrocalcinosis, and to elucidate the risk factor of nephrocalcinosis in patients with hypophosphatemic rickets. We followed six patients. The median age at diagnosis was 3.25 (0.75–10.5) years. The median follow-up duration was 8.25 (3.5–12.5) years. The mean dose of calcitriol and phosphate treatments was 39.1±8 ng/kg/day, 90.5±57.1 mg/kg/day, respectively. Nephrocalcinosis was detected in three patients (50%). The mean dose of phosphate taken by the patients found to have nephrocalcinosis was detected to be high with a statistically significant difference (p=0.041). No significant relationship was found the mean dose of calcitriol. We found no relationship between the development of nephrocalcinosis and the incidence of hypercalciuria or hypercalcemia episodes. We found the increased phosphate dose administered for treatment to play a role in nephrocalcinosis development.


Corresponding author: Melikşah Keskin, Dr. Sami Ulus Women Health, Children’s Training and Research Hospital, Division of Pediatric Endocrinology, Department of Pediatrics, Ankara, Turkey, Phone: +905056236895, Fax: +9003123170353, E-mail:

References

1. Vaisbich MH, Koch VH. Hypophosphatemic rickets: results of a long-term follow-up. Pediatr Nephrol 2006;21:230–4.10.1007/s00467-005-2077-4Suche in Google Scholar

2. Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician’s guide to X-linked hypophosphatemia. J Bone Miner Res 2011;26:1381–8.10.1002/jbmr.340Suche in Google Scholar

3. de Menezes Filho H, de Castro LC, Damiani D. Hypophosphatemic rickets and osteomalacia. Arq Bras Endocrinol Metab 2006;50:802–13.10.1590/S0004-27302006000400025Suche in Google Scholar

4. Kooh SW, Binet A, Daneman A. Nephrocalcinosis in X-linked hypophosphatemic rickets: its relationship to treatment, kidney function, and growth. Clin Invest Med 1994;17:123–30.Suche in Google Scholar

5. Verge CF, Lam A, Simpson JM, Cowell CT, Hoeard NJ, et al. Effects of therapy in X-linked hypophosphatemic rickets. N Eng J Med 1991;325:1843–8.10.1056/NEJM199112263252604Suche in Google Scholar

6. Alon U, Donaldson DL, Hellerstein S, Warady BA, Harris DJ. Metabolic and histologic investigation of the nature of nephrocalcinosis in children with hypophosphatemic rickets and in the Hyp mouse. J Pediatr 1992;120:899–905.10.1016/S0022-3476(05)81957-2Suche in Google Scholar

7. Seikaly M, Browne R, Baum M. Nephrocalcinosis is associated with renal tubular acidosis in children with X-linked hypophosphatemia. Pediatrics 1996;97:91–3.Suche in Google Scholar

8. Kruse A, Dracht U, Gopfert G. Renal threshold phosphate concentration (TmPO4/GFR). Arch Dis Child 1982;57:217–23.10.1136/adc.57.3.217Suche in Google Scholar PubMed PubMed Central

9. Brodehl J, Krause A, Hoyer P. Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijvoet. Pediatr Nephrol 1988;2:183–9.10.1007/BF00862587Suche in Google Scholar PubMed

10. Lietman SA, Germain-Lee EL, Levine MA. Hypercalcemia in children and adolescents. Curr Opin Pediatr 2010;22:508–15.10.1097/MOP.0b013e32833b7c23Suche in Google Scholar PubMed PubMed Central

11. Patriquin H, Robitaille P. Renal calcium deposition in children: sonographic demonstration of the Anderson-Carr progression. Am J Roentgenol 1986;146:1253–6.10.2214/ajr.146.6.1253Suche in Google Scholar PubMed

12. Root AW, Diamond FB Jr. Disorders of calcium metabolism in the child and adolescent. In: Sperling MA, editor. Pediatric endocrinology, 2nd ed. Philadelphia: Saunders, 2002:646.Suche in Google Scholar

13. Makitie O, Doria A, Kooh SW, Cole WG, Daneman A, Sochett E. Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 2003;88:3591–7.10.1210/jc.2003-030036Suche in Google Scholar PubMed

14. Friedman NE, Lobaugh B, Drezner MK. Effects of calcitriol and phosphorus therapy on the growth of patients with X-linked hypophosphatemia. J Clin Endocrinol Metab 1993;76:839–44.Suche in Google Scholar

15. Lee JY, Imel EA. The changing face of hypophosphatemic disorders in the FGF-23 era. Pediatr Endocrinol Rev 2013;10(Suppl 2):367–79.Suche in Google Scholar

16. Patzer L, van’t Hoff W, Shah V, Hallson P, Kasidas GP, et al. Urinary supersaturation of calcium oxalate and phosphate in patient with X-linked hypophosphatemic rickets and in healthy schoolchildren. J Pediatr 1999;135:611–7.10.1016/S0022-3476(99)70060-0Suche in Google Scholar

17. Schonaue E, Kruse K, Bohles HJ, Sewell AC. More evidence for hyperoxaluria in phospha-tetreated X-linked familial hypophosphatemic rickets. Eur J Pediatr 1992;151:390.10.1007/BF02113269Suche in Google Scholar PubMed

18. Reusz GS, Hoyer PF, Lucas M, Krohn HP, Ehrich JH, et al.. X-Linked hypophosphatemic: treatment, height gain, and nephrocalcinosis. Arch Dis Child 1990;65:1125–8.10.1136/adc.65.10.1125Suche in Google Scholar PubMed PubMed Central

19. Glorieux FH. Hypophosphatemic vitamin D-resistant rickets. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism, 5th ed. Washington: American Society for Bone and Mineral Research, 2003:7.Suche in Google Scholar

Received: 2014-10-29
Accepted: 2015-5-4
Published Online: 2015-7-23
Published in Print: 2015-11-1

©2015 by De Gruyter

Artikel in diesem Heft

  1. Frontmatter
  2. Highlight: Turner syndrome
  3. Turner syndrome – working together with patients and their families
  4. Turner syndrome patients with bicuspid aortic valves and renal malformations exhibit abnormal expression of X-linked inhibitor of apoptosis protein (XIAP)
  5. Inhibin B in adolescents and young adults with Turner syndrome
  6. Mode of initial presentation and chromosomal abnormalities in Irish patients with Turner syndrome: a single-centre experience
  7. Retrospective evaluation of pubertal development and linear growth of girls with Turner Syndrome treated with oral and transdermal estrogen
  8. Turner syndrome in Albania and the efficacy of its treatment with growth hormone
  9. Review articles
  10. The relation of vitamin D status with metabolic syndrome in childhood and adolescence: an update
  11. Putting the pieces together: cryptorchidism – do we know everything?
  12. Original articles
  13. Investigation of androgen receptor gene mutations in a series of 21 patients with 46,XY disorders of sex development
  14. Molecular diagnosis of maturity-onset diabetes of the young (MODY) in Turkish children by using targeted next-generation sequencing
  15. Association of physical activity level with depression, anxiety, and quality of life in children with type 1 diabetes mellitus
  16. Neonatal diabetes in Ukraine: incidence, genetics, clinical phenotype and treatment
  17. The effect of intraoperative administration of dexamethasone for PONV prophylaxis on perioperative blood glucose level in obese and normal weight children
  18. Are obesity and metabolic syndrome associated with plasma adropin levels in children?
  19. Carnitine insufficiency in children with inborn errors of metabolism: prevalence and treatment efficacy
  20. Comparison of energy expenditure, body composition, metabolic disorders, and energy intake between obese children with a history of craniopharyngioma and children with multifactorial obesity
  21. Effect of serum cholesterol on bone mineral density in normal-weight children and adolescents
  22. Assessment of bone turnover markers and bone mineral density in normal short boys
  23. Long-term treatment for hyperphenylalaninemia and phenylketonuria: a risk for nutritional vitamin B12 deficiency?
  24. Risk factors affecting the development of nephrocalcinosis, the most common complication of hypophosphatemic rickets
  25. Children with hyperthyroidism younger than age 7 require higher mg/kg doses of methimazole to normalize free T4 compared to older children
  26. Effects of bisphosphonates to treat osteoporosis in children with cerebral palsy: a meta-analysis
  27. AMH levels at central precocious puberty and premature thelarche: is it a parameter?
  28. Validating Paediatric Morphometrics: body proportion measurement using photogrammetric anthropometry
  29. Treatment of central precocious puberty and early puberty with GnRH analog in girls with Williams-Beuren syndrome
  30. Short communication
  31. Pilot study on the dietary habits and lifestyles of girls with idiopathic precocious puberty from the city of Rome: potential impact of exposure to flame retardant polybrominated diphenyl ethers
  32. Patient reports
  33. Hypomagnesemia due to two novel TRPM6 mutations
  34. A novel mutation of AMH in three siblings with persistent Mullerian duct syndrome
  35. Kocher-Debré-Semelaigne syndrome with rhabdomyolysis and increased creatinine
  36. Anaphylaxis to gonadorelin acetate in a girl with central precocious puberty
  37. Efficacy and safety of sirolimus in a neonate with persistent hypoglycaemia following near-total pancreatectomy for hyperinsulinaemic hypoglycaemia
Heruntergeladen am 21.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/jpem-2014-0447/html
Button zum nach oben scrollen